Stocks · News reference
XORTX Therapeutics shares are trading higher after the company outlined its anticipated IND application submission to the FDA for the XRx-026 gout program.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
XORTX Therapeutics Plans Health Canada Clinical Trial Application For Gout Drug XORLO Ahead Of Planned FDA Filing